Delivery Order SPE2DR25D3103-SPE2DR26F9R08
- Not listed
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Actemra ActPen (162 mg/0.9 mL) auto-injectors. This firm fixed price delivery order carries a ceiling value of $3,066.26 and is scheduled for completion by August 19, 2025. The contract was competitively awarded without set-aside provisions, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements....
- The Defense Logistics Agency awarded a $13,292.11 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Actemra (tocilizumab) Actpen 162 mg/0.9 mL auto-injectors. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's facility...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant used to treat rheumatoid arthritis and other inflammatory...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,066.95 by the Defense Logistics Agency (DLA) on July 24, 2025, with ultimate completion scheduled for July 25, 2025. The contract covers the supply of Actemra ActPen 162 mg/0.9 mL injections and was awarded through competitive bidding without set-aside designation under a firm fixed-price arrangement. This delivery order operates as a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award from the Defense Logistics Agency (DLA) on September 9, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. The contract is valued at $3,431.82 with a firm fixed price structure and an ultimate completion date of September 10, 2025. This delivery order was awarded competitively with no set-aside designation and represents a child contract...
- The U.S. Department of Defense Medical Supply Chain awarded a $6,235.68 delivery order to AmerisourceBergen Drug Corp for Actemra ActPen 162 mg/0.9 ml auto-injectors. This firm fixed-price, non-set-aside contract was executed on August 11, 2025, with an ultimate completion date of August 12, 2025. The award represents a child delivery order under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through...
- The Defense Logistics Agency awarded a delivery order valued at $2,310.51 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This contract, awarded on December 18, 2025, with an ultimate completion date of December 19, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. As a competitive award, this delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors with a ceiling value of $4,575.76. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The award is issued from the company's Corporate Office location in Conshohocken, Pennsylvania, with an ultimate completion date of November 5, 2025. This delivery order...
- The Defense Logistics Agency awarded a $49,591.32 delivery order to AmerisourceBergen Drug Corp for the supply of Actemra Actpen (tocilizumab) 162 mg/0.9 mL auto-injector pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with performance to be completed by September 29, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9R08Delivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order for Actemra ActPen 162 mg/0.9 mL auto-injectors by the Defense Logistics Agency on December 18, 2025, with an ultimate completion date of December 19, 2025. The contract is structured as a firm fixed-price delivery order with a ceiling value of $4,327.94 and carries no set-aside designation, indicating it was competitively awarded. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a prime vendor agreement valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. Actemra (tocilizumab) is a prescription medication used to treat various inflammatory and autoimmune conditions, including rheumatoid arthritis. The award reflects AmerisourceBergen's critical role as a pharmaceutical distributor to the Defense Health Agency and other federal healthcare systems. The company's extensive federal contract portfolio and substantial prime vendor agreement demonstrate its capacity to fulfill diverse and specialized medical supply requirements across multiple therapeutic domains in support of military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 12/17/25 |